Stock Moves Reflect Downgrade for US Economic Growth Outlook - Goldman
CCORF Maintains 10x Genomics(TXG.US) With Buy Rating, Maintains Target Price $32
10x Genomics Analyst Ratings
Leerink Partners Initiates 10x Genomics(TXG.US) With Buy Rating, Announces Target Price $35
Navigating 11 Analyst Ratings For 10x Genomics
10x Genomics Analyst Ratings
Morgan Stanley Maintains 10x Genomics(TXG.US) With Buy Rating, Cuts Target Price to $46
Buy Rating Affirmed for 10x Genomics Amidst Strategic Realignment and Promising Growth Prospects
Stifel Nicolaus Reaffirms Their Buy Rating on 10x Genomics (TXG)
Maintaining Hold: Balancing 10x Genomics' Growth Prospects With Economic and Strategic Challenges
10x Genomics (TXG) Receives a Buy From Barclays
Hold Rating on 10x Genomics Amidst Mixed Financial Performance and Market Uncertainties
Canaccord Genuity Adjusts Price Target on 10x Genomics to $32 From $50, Maintains Buy Rating
10x Genomics Analyst Ratings
CCORF Maintains 10x Genomics(TXG.US) With Buy Rating, Cuts Target Price to $32
10x Genomics Analyst Ratings
10x Genomics Analyst Ratings
10x Genomics Analyst Ratings
10x Genomics Stock Slides 14% Amid Illumina Deal, Deutsche Downgrade
Goldman Sachs Adjusts Price Target on 10x Genomics to $16 From $26, Maintains Sell Rating